# Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia

> **NCT04603508** · PHASE3 · UNKNOWN · sponsor: **EMS** · enrollment: 240 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus
- Dyslipidemia

## Interventions

- **DRUG:** BERLIM 25/10 association
- **DRUG:** EMPAGLIFLOZIN
- **DRUG:** ROSUVASTATIN CALCIUM
- **OTHER:** BERLIM 25/10 ASSOCIATION PLACEBO
- **OTHER:** EMPAGLIFLOZIN PLACEBO
- **OTHER:** ROSUVASTATIN CALCIUM PLACEBO

## Key facts

- **NCT ID:** NCT04603508
- **Lead sponsor:** EMS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03
- **Primary completion:** 2025-04
- **Final completion:** 2025-08
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2022-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04603508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04603508, "Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04603508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*